OHR Pharmaceutical Inc. (OHRP) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) Contrasting side by side

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 9.98M -3.54 0.00
Eiger BioPharmaceuticals Inc. N/A 0.00 46.78M -3.98 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of OHR Pharmaceutical Inc. and Eiger BioPharmaceuticals Inc.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -71.5% -66.8%
Eiger BioPharmaceuticals Inc. 0.00% -155.6% -85.1%

Risk & Volatility

OHR Pharmaceutical Inc.’s volatility measures that it’s 17.00% more volatile than S&P 500 due to its 1.17 beta. From a competition point of view, Eiger BioPharmaceuticals Inc. has a 1.47 beta which is 47.00% more volatile compared to S&P 500.

Liquidity

OHR Pharmaceutical Inc.’s Current Ratio is 5.4 while its Quick Ratio is 5.4. On the competitive side is, Eiger BioPharmaceuticals Inc. which has a 4.6 Current Ratio and a 4.6 Quick Ratio. OHR Pharmaceutical Inc. is better positioned to pay off short and long-term obligations compared to Eiger BioPharmaceuticals Inc.

Insider and Institutional Ownership

Roughly 12.7% of OHR Pharmaceutical Inc. shares are held by institutional investors while 86.9% of Eiger BioPharmaceuticals Inc. are owned by institutional investors. About 8.89% of OHR Pharmaceutical Inc.’s share are held by insiders. On the other hand, insiders held about 7.6% of Eiger BioPharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%
Eiger BioPharmaceuticals Inc. 2.07% -1.07% 34.93% 7.63% 48.71% 36.12%

For the past year OHR Pharmaceutical Inc. was less bullish than Eiger BioPharmaceuticals Inc.

Summary

OHR Pharmaceutical Inc. beats on 5 of the 6 factors Eiger BioPharmaceuticals Inc.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.